793695-85-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(Bromomethyl)-1-chloro-4-iodobenzene is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the creation of a wide range of medicinal compounds, contributing to the development of new drugs and therapies.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(Bromomethyl)-1-chloro-4-iodobenzene serves as an essential intermediate for the production of various agrochemicals. Its versatility in chemical reactions enables the synthesis of compounds that can be used in pest control and crop protection.
Used in Dye Production:
2-(Bromomethyl)-1-chloro-4-iodobenzene is utilized in the production of dyes due to its ability to form colored compounds. Its presence in the chemical structure of dyes contributes to the color intensity and stability, making it valuable in the textile and other industries that rely on colorants.
Used in Industrial Chemical Production:
2-(BROMOMETHYL)-1-CHLORO-4-IODOBENZENE is also employed in the manufacturing of other industrial chemicals. Its role as a building block in chemical synthesis allows for the creation of a diverse array of products used across various industries, highlighting its importance in the chemical manufacturing process.

Upstream product

• 116632-41-8 1-chloro-4-iodo-2-methylbenzene 

Downstream Products

• 1103738-29-9 1-chloro-2-(4-ethoxybenzyl)-4-iodobenzene 
• 1049811-45-1 3-(2-Chloro-5-iodo-benzyloxy)-propan-1-ol 
• 793695-74-6 (1'S,2'R,3'S,4'R,5'S)-4'-[6-(2-chloro-5-(3-hydroxypropynyl)benzylamino)-2-chloropurin-9-yl]-2',3'-O-isopropylidenebicyclo[3.1.0]haxane-1'-carboxylic acid ethyl ester 
• 793695-65-5 (1'S,2'R,3'S,4'R,5'S)-4'-[6-(2-chloro-5-iodobenzylamino)-2-chloropurin-9-yl]-2',3'-O-isopropylidenebicyclo[3.1.0]haxane-1'-carboxylic acid ethyl ester 
• 793695-92-8 2-chloro-5-(3-hydroxypropynyl)benzylamine 
• 793695-90-6 2-chloro-5-iodobenzylamine 
• 793695-87-1 N-(2-chloro-5-iodobenzyl)phthalimide 
• 1067197-12-9 methyl N-[[2-chloro-5-[1-(4-methylphenyl)methyl-1H-1,2,3-triazol-4-yl]phenyl]methyl]carbamate 
• 1067197-09-4 methyl N-[[2-chloro-5-[2-(4-methylphenyl)methyl-2H-1,2,3-triazol-4-yl]phenyl]methyl]carbamate 
• 1067197-10-7 methyl N-[[2-chloro-5-[2-(4-chlorophenyl)-2H-1,2,3-triazol-4-yl]phenyl]methyl]carbamate 
• 1067197-11-8 methyl N-[[2-chloro-5-[1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl]phenyl]methyl]carbamate 
• 1067197-08-3 methyl N-[[2-chloro-5-(1H-1,2,3-triazol-5-yl)phenyl]methyl]carbamate 
• 251084-97-6 methyl N-[[2-chloro-5-ethynylphenyl]methyl]carbamate 
• 251085-25-3 methyl N-[[2-chloro-5-[2-(trimethylsilyl)ethynyl]phenyl]methyl]carbamate 

Relevant academic research and scientific papers

First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate

Inhibition of neuronal nitric oxide synthase (nNOS), an enzyme implicated in neurodegenerative disorders, is an attractive strategy for treating or preventing these diseases. We previously developed several classes of 2-aminoquinoline-based nNOS inhibitor

2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their preparation, to

2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2- yl)picolinamide derivatives of formula (I) Formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their pre

SUBSTITUTED BENZENE FUNGICIDES

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein W is O or S; V is a direct bond or NR3; Q is or CR6aR6b, O, NR7, C=N-O-R7 or C(=O)

PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS

Disclosed are (N)-methanocarba adenine nucleosides of the formula: [Formula] as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.

(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists

A series of ring-constrained (N)-methanocarba-5′-uronamide 2,N 6-disubstituted adenine nucleosides have been synthesized via Mitsunobu condensation of the nucleobase precursor with a pseudosugar ring containing a 5′-ester functionality. Following appropriate functionalization of the adenine ring, the ester group was converted to the 5′-N-methylamide. The compounds, mainly 2-chloro-substituted derivatives, were tested in both binding and functional assays at human adenosine receptors (ARs), and many were found to be highly potent and selective A3-AR agonists. Selected compounds were compared in binding to the rat A3AR to assess their viability for testing in rat disease models. The N 6-(3-chlorobenzyl) and N6-(3-bromobenzyl) analogues displayed Ki values at the human A3AR of 0.29 and 0.38 nM, respectively. Other subnanomolar affinities were observed for the following N6 derivatives: 2,5-dichlorobenzyl, 5-iodo-2-methoxybenzyl, trans-2-phenyl-1-cyclopropyl, and 2,2-diphenylethyl. Selectivity for the human A3AR in comparison to the A1AR was the following (fold): the N6-(2,2-diphenylethyl) analogue 34 (1900), the N 6-(2,5-dimethoxybenzyl) analogue 26 (1200), the N6-(2,5- dichlorobenzyl) and N6-(2-phenyl-1-cyclopropyl) analogues 20 and 33 (1000), and the N6-(3-substituted benzyl) analogues 17, 18, 28, and 29 (700-900). Typically, even greater selectivity ratios were obtained in comparison with the A2A and A2BARs. The (N)-methanocarba-5′-uronamide analogues were full agonists at the A 3AR, as indicated by the inhibition of forskolin-stimluated adenylate cyclase at a concentration of 10 μM. The N6-(2,2-diphenylethyl) derivative was an A3AR agonist in the (N)-methanocarba-5′- uronamide series, although it was an antagonist in the ribose series. Thus, many of the previously known groups that enhance A3AR affinity in the 9-riboside series, including those that reduce intrinsic efficacy, may be adapted to the (N)-methanocarba nucleoside series of full agonists.